Africa (Commonwealth Union) _ Medical advocacy groups are celebrating a pivotal move by Johnson & Johnson to relinquish its patent rights on a vital tuberculosis (TB) medication, paving the way for significantly more affordable production. This development follows an investigation by South African authorities into the pharmaceutical giant’s practices.
On July 5, the South African Competition Commission announced its decision not to pursue a complaint against J&J regarding allegations of market dominance abuse. This complaint emerged after J&J and its subsidiary sought to secure a secondary patent for bedaquiline, a key treatment for drug-resistant TB. Experts contended that the patent hindered generic manufacturers from producing cost-effective alternatives, endangering the treatment of thousands of South Africans. TB claimed over 50,000 lives in South Africa in 2021, making it the nation’s leading cause of death.
Authorities have since confirmed that J&J will not enforce its patent and will reduce the price of bedaquiline for South Africa by approximately 40%. Candice Sehoma, an advocacy advisor at Doctors Without Borders in South Africa, praised the decision, stating, “We hope this sends a strong message to pharma that they cannot continue their anti-competitiveness monopoly and prioritize profits over people’s lives.”
Sehoma also expressed hope that local generic manufacturers will soon begin producing bedaquiline, noting that Indian factories already manufacture the drug. Last year, activists from India, Belarus, and Ukraine rallied against J&J’s efforts to maintain its patent on bedaquiline, though their actions initially saw little impact. The company’s application to extend its South African patent until 2027 sparked outrage among activists, who accused J&J of profiteering.
In a bold challenge to the dominance of major pharmaceutical companies, the South African government launched an investigation into J&J’s pricing strategies. At the time, South Africa was paying around 5,400 rand ($282) per treatment course, a stark contrast to poorer nations benefiting from the global Stop TB Partnership initiative.
Fatima Hassan, founder of the Health Justice Initiative in South Africa, highlighted the broader implications of this decision. She suggested that patenting tactics for other crucial medications, including those for HIV, cancer, and cystic fibrosis, might also come under scrutiny for their pricing policies. “Pharmaceutical corporations need to be held in check and accountable,” Hassan stated.
This significant victory against pharmaceutical monopolies not only promises more affordable TB treatments in South Africa but also sets a precedent for challenging exorbitant drug pricing worldwide. As generic manufacturers gear up to produce bedaquiline, the hope is that this breakthrough will ignite further reforms in the global healthcare landscape.
